Senicapoc in Alzheimer's Disease
NCT04804241
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Development of novel disease-modifying therapies for Alzheimer's disease (AD) remains of paramount importance. This study will be a Phase II randomized clinical trial testing Senicapoc in patients with mild or prodromal AD. This will be a small Proof of Mechanism study to prove biological activity and target engagement in humans with early AD. The investigators will study up to 55 patients over 52 weeks, with primary outcomes being Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) scores and blood and cerebrospinal fluid (CSF) markers of neuroinflammation.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Mild Cognitive Impairment
- Alzheimer Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 55 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- University of California, Davis
- Last updated on ClinicalTrials.gov
- August 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- University of California, Davis Alzheimer's Disease Center · Sacramento, CA
- UC Davis Alzheimer's Disease Center East Bay · Walnut Creek, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.